top of page

OUR TEAM

After more than a decade of foundational studies involving protease-activated receptors (PARs), Function Therapeutics, Inc. was founded in 2021 to advance a new class of PAR-targeting anti-inflammatories to the clinic. The original partnership between the labs of Dr. Robert Flaumenhaft (Harvard Medical School) and Dr. Chris Dockendorff (previously at Marquette Univ.) is the foundation for an integrated team of executives, consultants, and collaborators with decades of experience in disease biology, structural biology, medicinal chemistry, and pharmacology.

IMG_0402.JPG

Chris Dockendorff, PhD

CSO & CEO

Dr. Dockendorff is an organic and medicinal chemist with a passion for the design, synthesis, and study of novel molecules with the potential to improve human health. 

  • LinkedIn

Paul Ornstein, Ph.D.

VP of Preclinical Development

Dr. Ornstein has close to 40 years of drug discovery experience as a medicinal chemist at Eli Lilly, followed by faculty positions at Roosevelt University and the Medical College of Wisconsin.

  • LinkedIn
Peter Suzdak Photo 2.jpg

Peter Suzdak, Ph.D.

Consultant

Dr. Suzdak has more than 35 years of experience as a pharmaceutical scientist, executive, and leader of therapeutic startups.

  • LinkedIn

Executive Team

Allie-Huber.jpg

Allie Huber

Controller

  • LinkedIn
Breunig.jpeg

Steph Breunig

Human Resources

  • LinkedIn
Penley.jpg

Michael Penley

General Counsel

  • LinkedIn

Scientific Advisory Board

Greenlee.jpg

William Greenlee, Ph.D.

Dr. Greenlee is an independent medicinal chemistry consultant and former senior director and VP of chemistry at Merck Research Labs & Schering-Plough Research Institute.

Function-Therapeutics_Hartmut Weiler.webp

Hartmut Weiler, Ph.D.

Dr. Weiler is a Senior Investigator at the Versiti Blood Research Institute. He is a world expert in coagulation, inflammation biology, sepsis, and hematopoesis.

Flaumenhaft.jpg

Robert Flaumenhaft, M.D., Ph.D.

Dr. Flaumenhaft is Professor of Medicine at Harvard Medical School and presently Chief of the Division of Hemostasis & Thrombosis at Beth Israel Deaconess Medical Center.

Function-Therapeutics_Berend Isermann.webp

Berend Isermann, M.D.

Dr. Isermann is Professor of Laboratory Medicine and Clinical Chemistry at Leipzig University. In 2018 he received the German Bioregion Innovation Prize.

Our Partners & Funding Organizations

Function-Therapeutics_2016 09 Trevor sep funnel_JPG.webp

Photo Credit: Dan Johnson

bottom of page